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OBJECTIVES The aim of this study was to analyze modifications in the plasma protein map during an acute
coronary syndrome (ACS) using proteomics.
BACKGROUND Proteomics is a new technology that allows the detection and identification of several proteins
at a given time in a sample.
METHODS Plasma from 19 patients, 11 with acute myocardial infarction (AMI) and 8 with unstable
angina (UA), was investigated. The control group included nine age-matched volunteers.
RESULTS In two-dimensional electrophoresis using a pH range of 4 to 7, constant differences were
found in at least four different areas within the plasma protein map. In area 1, we identified
the presence of seven alpha1-antitrypsin (AAT) isoforms in plasma from control subjects.
alpha1-antitrypsin isoform 1 was undetectable in plasma from UA and AMI patients. The
AAT isoforms 5, 6, and 7 were reduced in plasma from AMI patients when compared with
UA patients. Three fibrinogen gamma chain isoforms were identified in area 2. Fibrinogen
gamma chain isoforms 1 and 2 were increased in AMI patients with respect to UA patients.
Five apolipoprotein A-I isoforms were identified in area 3. All of them were reduced in
plasma from AMI patients with respect to UA patients. In area 4, the -immunoglobulin
heavy chains were detected and were found increased in plasma from ACS patients.
CONCLUSIONS Plasma proteomic analysis makes it possible to develop a map of the protein isoforms that are
expressed in plasma during an ACS. (J Am Coll Cardiol 2004;44:1578–83) © 2004 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.06.073American College of Cardiology Foundation
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peveral studies have demonstrated changes in the plasma
evels of biomarkers related to inflammation, platelet acti-
ation, coagulation, myocyte necrosis, and plaque rupture in
atients with acute coronary syndromes (ACS) (1–3). Most
f these plasma biomarkers are associated with clinical
rognosis (4,5). Until now the investigators had to analyze
ach biomarker one by one. However, a technology termed
See page 1584
roteomics has been recently developed to obtain a map of
he proteins expressed in tissues, cells, or fluids, including
lasma (6). Proteomics is the study of the proteome. The
lasma proteome consists of all the proteins present at a
iven time in it, including the variety of modified proteins
rising from alternative splicing of transcripts and/or from
ost-translational processing, resulting in modifications that
an alter protein structure and/or function.
From the *Cardiovascular Institute, Hospital Clı´nico San Carlos, Madrid, Spain;
nd †Emergency Unit and ‡Epidemiology Department, Cardiovascular Research
aboratory, Fundación Jiménez Dı´az, Madrid, Spain. Supported by Fondo de
nvestigaciones de la Seguridad Social (Redes Temáticas de Cooperación; Red
ardiovascular C01/03 and Red Heracles) and Laboratories Uriach.w
Manuscript received December 16, 2003; revised manuscript received April 21,
004, accepted June 16, 2004.Proteomics uses a combination of techniques, including
wo-dimensional gel electrophoresis, image analysis, and
ass spectrometry (7). This technique has been extensively
mployed to investigate cancer and other diseases (8,9), but
here are currently no reports concerning the proteomic
tudy of plasma from patients during ACS. In this study, we
sed proteomics to analyze modifications in the plasma
rotein map during unstable angina (UA) and acute myo-
ardial infarction (AMI).
ETHODS
atients. Nineteen patients admitted to the Emergency
nit of Fundación Jiménez Dı´az were investigated. Eleven
ad transmural AMI based on prolonged chest pain,
hanges on standard electrocardiogram, and raised serum
reatine kinase (2-fold upper limit of normal value of the
iochemical laboratory) and creatine kinase, MB fraction
10% total creatine kinase). Eight patients had UA based
n chest pain at rest and transient S-T segment changes,
ithout significant increases in creatine kinase and creatine
inase, MB fraction. The control group included nine
ge-matched volunteers.
The criterion for enrollment was admission within 24 h
fter the onset of chest pain. A criterion for exclusion was a
revious episode of ACS. Because this work is included
ithin a study to analyze molecular mechanisms of anti-
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xposure (during the preceding two weeks) to antithrom-
otic, steroidal and nonsteroidal anti-inflammatory drugs,
nd heparin. Moreover, patients or control subjects with a
istory of neoplastic, infectious, or autoimmune diseases or
ny surgical procedure in the preceding six months were not
ncluded. All subjects gave informed consent, and the study
as approved by the ethics committee of Fundación
iménez Dı´az.
wo-dimensional electrophoresis (2-DE). For 2-DE,
50 g of plasma were diluted in 350 l of 8 mol/L urea,
% CHAPS w/v, 40 mmol/l dithiothreitol, 0.2 % Bio-Lyte
mpholyte (Bio-Rad Labs, Hercules, California), and
.01% w/v bromophenol blue. The samples were loaded on
mmobilized pH gradient gel strips (pH 3 to 10 or pH 4 to
), and isoelectric focusing was performed using a Protean
EF cell system (Bio-Rad Labs). The gels were actively
ehydrated at 50 V for 60 h, then rapid and linear voltage
amping steps, limited by a maximum current of 50 A per
el, were applied at 250 V, 10,000 V, 10,000 V (30,000 Vh).
n the second dimension, the proteins from the strips were
esolved on 10% sodium dodecyl sulfate-polyacrylamide gel
lectrophoresis gels using a Protean II XL system (Bio-Rad
Table 1. Characteristics of the Groups Studied
Age-Ma
Control
(n 
Age (yrs) (SEM) 60.78
Male/female 6/
Risk factors, n (%)
Tobacco smoking 2 (22%
Hypertension 5 (55.
Hypercholesterolemia
(total cholesterol 200 mg/dl)
0 (0%
Diabetes mellitus 2 (22%
Medication on admission, n (%)
Beta-blockers 0 (0%
Calcium antagonists 1 (11%
ACE inhibitors 0 (0%
Diuretics 0 (0%
Nitrates 0 (0%
Statins 0 (0%
Abbreviations and Acronyms
AAT  alpha1-antitrypsin
ACS  acute coronary syndrome
AMI  acute myocardial infarction
Apo A-I  apolipoprotein A-I
2-DE  bidimensional electrophoresis
MALDI-TOF MS  matrix-assisted laser desorption/
ionization-time of flight mass
spectrometry
MS/MS  tandem mass spectrometry
UA  unstable anginaACE  angiotensin-converting enzyme.abs). Afterwards, the gels were fixed and silver stained. At
east two different gels were run per patient.
ilver staining. The gels were fixed in a solution contain-
ng a Fixative Enhance Concentrate solution (Bio-Rad
abs), methanol, and acetic acid in distilled water for 20
in. After two 10-min washings in distilled water, gels were
tained using a Silver Stain Plus Kit. Development was
erformed for approximately 25 min and stopped with 5%
cetic acid. The stained gels were then washed twice in
istilled water for 5 min each time.
mage acquisition and analysis. The stained gels were
canned in a UMAX POWERLOOK III Scanner operated
y the software Magic Scan V 4.5. Intensity calibration was
arried out using an intensity stepwedge before gel image
apture. Image analysis was carried out using PD Quest
.2.1 and Quantity One 4.2.3 (Bio-Rad Labs). Image spots
ere initially detected, matched, and then manually edited.
ach spot intensity volume was processed by background
ubtraction, and total spot volume was normalized by the
orresponding spot volume of albumin.
ass spectrometry. The spots of interest were manually
xcised from the gels using biopsy punches. To identify the
pots of interest by mass spectrometry, five different subjects
rom each experimental group were chosen. For each subject,
he spots of interest were isolated from two different gels.
roteins selected for analysis were in-gel reduced, alkylated,
nd digested with trypsin. Briefly, the spots were washed twice
ith water, shrunk with 100% acetonitrile, and dried in a
avant SpeedVac. Afterwards, the samples were reduced with
ithioerytritol in ammonium bicarbonate and subsequently
lkylated with iodoacetamide in ammonium bicarbonate. Fi-
ally, the samples were digested with 12.5 ng/l sequencing
rade trypsin (Roche Molecular Biochemicals, Barcelona,
pain) in 25 mM ammonium bicarbonate (pH 8.5). After
igestion, the supernatant was collected and 1 l was spotted
nto a matrix-assisted laser desorption/ionization (MALDI)
p
Unstable
Angina Group
(n  8)
Acute
Myocardial
Infarction Group
(n  11)
76.8 2.5 62.3 3.4
5/3 6/5
2 (25.0%) 4 (36.4%)
4 (50.0%) 3 (27.3%)
1 (12.5%) 6 (54.5%)
2 (25.0%) 1 (9.1%)
0 (0%) 0 (0%)
5 (62.5%) 1 (9.1%)
1 (12.5%) 1 (9.1%)
2 (25.0%) 1 (9.1%)
7 (87.5%) 11 (100%)
1 (12.5%) 1 (9.1%)tched
Grou
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MALDI-TOF MS) analyses were performed in a
oyager-DE STR instrument (PerSeptives Biosystems, Fra-
ingham, Massachusetts), a model fitted with a 337-nm
itrogen laser and operated in reflector mode, with an accel-
rating voltage of 20,000 V. All mass spectra were calibrated
xternally using a standard peptide mixture (Sigma-Aldrich,
adrid, Spain). Peptides from the autodigestion of trypsin
ere used for internal calibration. The analysis by MALDI-
OF MS produces peptide mass fingerprints, and the peptides
bserved can be collated and represented as a list of monoiso-
opic molecular weights. Tandem mass spectrometry (MS/
S) was performed when: 1) the individual ion scores of the
eptide mass fingerprints (score is10 Log [P] where P is the
robability that the observed match is a random event) did not
each identity or extensive homology with proteins contained
igure 1. (Left) Two-dimensional gel of plasma from a control volunteer
f subjects. (Right) Representative bidimensional electrophoresis gel imag
ngina (UA), and age-matched control subjects using a pH range of 4 to 7
n each of the other areas.
able 2. Identification of the Analyzed Proteins
Protein
Peptides
Matched Con
lpha-1-antitrypsin 3–10 MS, p
polipoprotein A-I 17–55 MS, p
ibrinogen gamma chain 8–10 MS, p
nmunoglobulin gamma heavy chain — Plasma
lbumin — PlasmaS: mass spectrometry; MALDI-TOF MS analyses (10); Plasma map: SWISS-PROT 2
MALDI-TOF MS  matrix-assisted laser desorption/ionization time of flight mass spn the Mascot database (10) or 2) peptides with similar ions
cores matched different proteins. In some cases, MS/MS was
arried out using the MALDI-tandem time-of-flight mass
pectrometer 4700 Proteomics Analyzer (Applied Biosystems,
ramingham, Massachusetts). The MS was performed by the
enomics and Proteomics Unit of Universidad Complutense,
adrid, Spain.
tatistical methods. Results are expressed as means 
EM. To determine statistical significance, we performed
he Mann-Whitney test. A p value 0.05 was considered
tatistically significant.
ESULTS
rotein separation. Table 1 shows the clinical features of
he patients. Figure 1 shows a representative two-
a pH range of 3 to 10. Four areas were analyzed (1 to 4) in each group
plasma from patients during acute myocardial infarction (AMI), unstable
min was identified in area 5 and was used to normalize total spot volume
ion Method
Sequence
Coverage (MS)
Sequence
Coverage (MS/MS)
map 13%–58% —
map, MS/MS 22%–86% 4%
map, MS/MS 16%–28% 3%
— —
— —using
es offirmat
lasma
lasma
lasma
map
mapD database (11); MS/MS: Tandem mass spectrometry (12).
ectrometry.
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pots were detected ranging from 15 to 200 kDa with a
H between 3 and 10. Four different areas localized
ithin a pH range of 4 to 7 in the proteomic plasma map
1 to 4) were observed showing constant differences
etween the different experimental groups (Fig. 1, left).
wo-dimensional amplifying gels with a pH range of 4 to
were run (Fig. 1, right).
rotein identification. The most remarkable spots whose
ensity had changed in these areas were densitometrically
easured and identified by comparison with those in the
WISS-2D database plasma map (11) (Table 2). Their
dentity was confirmed by mass spectrometry (Table 2). For
his purpose, they were subjected to MALDI-TOF MS and
atabase searching (12). When required, MS/MS was
urther performed (Table 2). Densitometric analysis of each
pot was calculated with albumin as reference (detected in
rea 5).
Alpha1-antitrypsin (AAT) was identified in area 1. In
ontrol subjects, we detected seven different isoforms num-
igure 2. Representative pattern of alpha1-antitrypsin (AAT-1) in plasma
rom patients during acute myocardial infarction (AMI), unstable angina
UA), and age-matched control subjects. Images were obtained from the
idimensional electrophoresis gels using a pH range of 4 to 7. Numbers 1
o 7 were only used to identify each AAT isoform.
able 3. -1-Antitrypsin Isoforms in Plasma From Patients Dur
Protein Map Area
Experimental Mass
(kDa/pI)
AT isoform 1 1 53.5/5.1
AT isoform 2 1 55.6/5.0
AT isoform 3 1 54.8/5.0
AT isoform 4 1 56.1/5.0
AT isoform 5 1 56.5/4.9
AT isoform 6 1 56.2/4.9
AT isoform 7 1 56.1/4.9
p 0.05 with respect to age-matched control group. †p 0.05 with respect to unstab
rom healthy volunteers and patients during unstable angina and acute myocardial infarctio
AAT  -1-antitrypsin; AU  arbitrary units; UD  undetectable.ered 1 to 7 (Fig. 2). In both UA and AMI, isoform 1 was
ndetectable (Fig. 2, Table 3). Isoforms 5, 6, and 7 in UA
nd isoforms 6 and 7 in AMI were increased with respect to
ontrol subjects (Table 3). Moreover, isoforms 5, 6, and 7
ere significantly reduced in AMI when compared with UA
Table 3).
In area 2, we observed three isoforms of fibrinogen
amma chain (Fig. 3, Table 4). Isoforms 1 and 2 were
ignificantly increased in ACS when compared with control
ubjects (Table 4) and were significantly increased in AMI
hen compared with UA (Table 4).
Five apolipoprotein A-I (Apo A-I) (area 3) isoforms were
bserved (Fig. 4). Four Apo A-I isoforms were significantly
educed in AMI when compared with control subjects
Table 5), and the five isoforms were significantly reduced in
MI when compared with UA (Table 5). Isoforms 2 and 3
ere significantly increased in UA when compared with
ontrol subjects (Table 5).
In area 4, the immunoglobulin gamma heavy chains were
etected and were significantly increased in ACS when
ompared with control subjects (Table 5).
igure 3. Representative pattern of fibrinogen gamma chain in plasma
rom patients during acute myocardial infarction (AMI), unstable angina
UA), and age-matched control subjects. Images were obtained from the
idimensional electrophoresis gels using a pH range of 4 to 7. Numbers 1
o 3 were only used to identify each fibrinogen gamma chain isoform.
n Acute Coronary Syndrome
Age-Matched
Control Group
(AU)
Unstable
Angina Group
(AU)
Acute Myocardial
Infarction Group
(AU)
28.8 1.08 U.D. U.D.
41.59 4.38 49.0  6.6 43.1  5.2
66.39 5.4 59.8  5.7 55.6  5.5
78.04 1.96 78.5  4.3 76.3  2.7
76.81 1.68 88.2  2.3* 80.4  2.2†
64.57 3.26 88.1  2.7* 77.2  3.2*†
44.75 3.67 80.9  3.4* 63.6  4.5*†
ina patients. Densitometric analysis of the different AAT isoforms detected in plasmaing a
le ang
n. Results are represented as mean  SEM.
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Human Plasma Proteome During Coronary Syndromes October 19, 2004:1578–83ISCUSSION
n this study, we show for the first time in a single map the
ifferent proteins expressed in plasma from patients during
n ACS, that is, UA and AMI, using proteomics. Proteom-
cs is a new technology that allows the determination of the
hanges found in several proteins in a sample obtained at a
iven time, mainly by using 2-DE.
One of the main findings was that the different AAT
soforms change in plasma during an ACS. The AAT is a
owerful inhibitor of several proteolytic enzymes, although
eutrophil elastase is clearly its primary protease target (13).
here is now ample evidence that, in the absence of enough
AT in the lower respiratory tract, there is an increased
urden of proinflammatory factors (14). We found seven
ifferent isoforms in control subjects. The AAT isoform 1
as not present in ACS. There was a significant reduction
f isoforms 5, 6, and 7 in AMI when compared with UA.
s a theory, these data open the possibility that AMI may
e associated with a failure to increase some AAT isoforms.
n this line of evidence, it has been suggested that low AAT
evels promote atherogenesis, and some AAT genotypes
ave been associated with a reduced risk of ischemic
erebrovascular and heart diseases (15,16). Moreover, AAT
an inhibit neutrophil superoxide production, and exoge-
ous administration of AAT conferred protection against
schemic/reperfusion injury (17,18). Another possibility is
hat during myocardial infarction significant quantities of
igure 4. Representative patterns of apolipoprotein A-I in plasma from
atients during acute myocardial infarction (AMI), unstable angina (UA),
nd age-matched control subjects. Images were obtained from the bidi-
able 4. Fibrinogen Gamma Chain Isoforms in Plasma From Pa
Protein Map Area
Experimental Mass
(kDa/pI)
GG isoform 1 2 49.5/5.3
GG isoform 2 2 49.4/5.4
GG isoform 3 2 49.4/5.6
p 0.05 with respect to age-matched control group. †p 0.05 with respect to unstab
rom healthy volunteers and patients during unstable angina and acute myocardial in
AU  arbitrary units; FGG  fibrinogen gamma chain.ensional electrophoresis gels using a pH range of 4 to 7. Numbers 1 to
were only used to identify each apolipoprotein A-I isoform.hese AAT isoforms may be consumed. Further character-
zation of the function of each AAT isoform may reveal
n-depth information about the mechanisms of ACS.
Fibrinogen is essential for fibrin formation under the
nfluence of thrombin and forms the basic plug for plasma
oagulation and platelet aggregation via glycoprotein IIb/
IIa receptors (19). Furthermore, fibrinogen increases the
inding of platelets, endothelial cells, and leukocytes to each
ther, which in turn causes leukocyte and platelet activation
nd release of mediators from these cells (20).
Fibrinogen contains two sets of three chains (alpha, beta,
nd gamma) linked by disulfide bonds (21). Activated
latelets bind to fibrin via the N-terminal of the beta-chain
nd the extreme C-terminal of the gamma chain (22).
arshall et al. (23), using mass spectral fingerprinting, have
dentified fibrinogen fragments in the serum of patients
uring myocardial infarction. In our study we detected three
ifferent fibrinogen gamma chain isoforms in plasma from
ormal and ACS patients. Two of them increased in AMI
ompared with UA. Interestingly, a different alternative
plicing of fibrinogen gamma chain messenger ribonucleic
cid has been recently demonstrated that results in fibrino-
en gamma chain variants that alter fibrin formation and
tructure and could be associated with increased thrombotic
isk (24).
Apolipoprotein A-I is a major component of high-
ensity lipoproteins. An inverse relationship between Apo
-I levels and coronary heart disease has been suggested
25,26). Indeed, several beneficial cardiovascular effects of
igh-density lipoproteins have been attributed to Apo A-I
27). In our study, we detected five Apo A-I isoforms in
ontrol plasma and in ACS. However, the expression of the
ve isoforms was greater in UA than in AMI. As a
ypothesis, the increased Apo A-I expression in UA com-
ared with AMI could be theoretically associated with the
everity of the coronary syndrome, UA versus AMI. Ac-
ordingly, increased Apo A-I during UA could imply an
ntagonistic response to the inflammatory reaction associ-
ted with the cardiac event. In fact, anti-inflammatory
roperties of Apo A-I have been reported (28).
We finally observed an increased level of immunoglobulin
amma heavy chains in ACS compared with control sub-
ects. This finding could be related to the inflammatory
haracter of ACS.
s During an Acute Coronary Syndrome
Age-Matched
Volunteers
(AU)
Unstable
Angina Group
(AU)
Acute Myocardial
Infarction Group
(AU)
16.9 1.43 33.0  2.4* 44.8  4.0*†
30.6 2.8 38.4  2.4* 51.2  3.7*†
32.4 3.74 36.6  3.6 42.2  4.8
ina patients. Densitometric analysis of the different FGG isoforms observed in plasma
n. Results are represented as mean  SEM.tient
le angProteomic analysis permits the detection of different
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easurement of the circulating biomarkers that could be
seful to understand the molecular mechanisms involved in
CS. Our observations should be interpreted with caution.
irst, quantification using two-dimensional electrophoresis
s not an exact method, because gel spots can contain
ultiple proteins and because mass spectrometry is not
uantitative. Therefore, other methods such as immuno-
lotting should be used. Also, the number of patients is small
nd larger groups are needed to establish the clinical impor-
ance of these findings. The present work is merely an example
f the use of proteomics to identify several protein isoforms at
given time in plasma from patients during an ACS.
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